Latest Articlesddd
Amgen Higher Dividends For those who invest in top-tier biotech firms for dividend payments, in addition …
The Week in Review #35 Politics and the Market The market tumbled today as Theresa May, …
Marinus Pharmaceuticals (MRNS) announced positive results from its Phase 2 clinical trials evaluating ganaxolone intravenous (IV), the …
Today, the market took another beating as a result of either an intentional or an unintentional …
Exelixis (EXEL) and Ipsen (Euronext: IPN; ADR: IPSEY) announced the initiation of COSMIC-312. A phase 3 pivotal trial of cabozantinib …
Another reason was found to hit the market when the economy is good and sustained and …
At the 60th American Society of Hematology (ASH) Annual Meeting CAR T is Still a Star With …
Prohost Letter #425 When Common Sense Fails to Explain the Market Performance It is not unusual …
Celyad (CYAD) is still a clinical-stage biopharmaceutical company developing advanced or improved CAR-T cell-based therapies. Today, …
Vertex Pharmaceuticals’ triple combination, which added the corrector VX-659 to the tezacaftor and ivacaftor combination, resulted …
As we expected in our posting yesterday under Today’s Highlights, the U.S. Food and Drug Administration (FDA) …
We hope you all took advantage of the Thanksgiving holiday to rest and relax. We did. …
This is just to inform that Europe has approved Cabometyx® (cabozantinib) tablets as a monotherapy for hepatocellular …
Aimmune Therapeutics (AIMT) has news. A lot of it is from a successful phase 3 trial …
The Week in Review #34 Improving on Immunotherapy and preventing one of its serious side effects. …
The Week in Review, which we will post soon, is going to provide news that cancer …
In today’s news Jazz Pharmaceuticals (JAZZ) announced the submission of a Marketing Authorization Application (MAA) to the European …
Yesterday, the Stock Market skyrocketed and with it a significant number of Prohost Picks that we …
RegenxBio (RGNX) has granted Abeona Therapeutics (ABEO) an exclusive worldwide license to its NAV AAV9 viral vector (subject …
Illumina (ILMN) and Pacific Biosciences (PACB) announced they have signed an agreement for Illumina to acquire Pacific Biosciences at a …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
